BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 8982753)

  • 61. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel.
    Rogers PA; Au CL; Affandi B
    Hum Reprod; 1993 Sep; 8(9):1396-404. PubMed ID: 8253925
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
    Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
    Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding.
    Hickey M; Dwarte D; Fraser IS
    Hum Reprod; 2000 Jul; 15(7):1509-14. PubMed ID: 10875858
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Benefits of vitamin E supplementation to Norplant users--in vitro and in vivo studies.
    Subakir SB; Setiadi E; Affandi B; Pringgoutomo S; Freisleben HJ
    Toxicology; 2000 Aug; 148(2-3):173-8. PubMed ID: 10962136
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
    Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding.
    Hickey M; Fraser IS
    Hum Reprod; 2002 Sep; 17(9):2428-34. PubMed ID: 12202436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.
    Zheng SR; Zheng HM; Qian SZ; Sang GW; Kaper RF
    Contraception; 1999 Jul; 60(1):1-8. PubMed ID: 10549446
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness of Norplant implants among Thai women in Bangkok.
    Chompootaweep S; Kochagarn E; Sirisumpan S; Tang-usaha J; Theppitaksak B; Dusitsin N
    Contraception; 1996 Jan; 53(1):33-6. PubMed ID: 8631187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NORPLANT contraceptive implants advancing.
    Segal SJ
    Netw Res Triangle Park N C; 1984; 5(3):1-3. PubMed ID: 12279797
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The measurement of endometrial perfusion in norplant users: a pilot study.
    Hickey M; Carati C; Manconi F; Gannon BJ; Dwarte D; Fraser IS
    Hum Reprod; 2000 May; 15(5):1086-91. PubMed ID: 10783358
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New contraceptives in the 1990s.
    O'Connell BJ
    Curr Opin Pediatr; 1995 Aug; 7(4):371-5. PubMed ID: 7581638
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Angiogenic effects of norplant contraception on endometrial histology and uterine bleeding.
    Pritts EA; Ryan IP; Mueller MD; Lebovic DI; Shifren JL; Zaloudek CJ; Korn AP; Darney PD; Taylor RN
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2142-7. PubMed ID: 15623808
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium.
    Charnock-Jones DS; Macpherson AM; Archer DF; Leslie S; Makkink WK; Sharkey AM; Smith SK
    Hum Reprod; 2000 Aug; 15 Suppl 3():85-95. PubMed ID: 11041225
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use.
    Hickey M; Dwarte D; Fraser IS
    Hum Reprod; 1998 Nov; 13(11):3190-6. PubMed ID: 9853879
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
    Croxatto HB; Díaz S; Pavez M; Brandeis A
    Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.